🇧🇷Brazil
Diversion and Duplicate Discount Violations in Contract Pharmacies
2 verified sources
Definition
Covered entities and retail contract pharmacies risk fraud/abuse through diversion of 340B drugs to non-patients or duplicate discounts when 340B drugs are billed to insurance yielding additional rebates. This is a core prohibition enforced via audits, leading to financial repayments. Recurring due to enforcement focus and software reliance.[1][3]
Key Findings
- Financial Impact: $Repayment of discounts to manufacturers per violation
- Frequency: Ongoing - identified in regular HRSA audits
- Root Cause: Insufficient tracking systems to prevent ineligible dispensing and poor visibility into claims at point-of-sale
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Retail Pharmacies.
Affected Stakeholders
Contract pharmacy staff, TPA operators, Covered entity auditors
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
HRSA Audit Failures and Required Repayments for Diversion/Duplicate Discounts
$Repayment of full discounts plus potential civil monetary penalties per audit
Failure to Receive 340B Ceiling Prices from Manufacturers
$Substantial savings lost (quantified as 'substantial reduction in available 340B savings') per year
Excess Labor and Overtime from Manual Compliance and Documentation Tasks
$1,000–$6,000 per store per month in additional labor and overtime associated with controlled‑substance record‑keeping and reconciliation
Delayed Reimbursement from Holds and Rejections on Controlled Substance Claims
$500–$4,000 per store per month in financing cost of delayed cash and staff time for claims follow‑up related to controlled substances
Rework and Corrective Actions from Controlled Substance Documentation Errors
$500–$3,000 per store per month in labor for rework and corrective actions, plus chain‑level project costs after adverse audit findings
Medicare Fraud Risk from Unbilled Parallel MTM Services
Full service value plus fraud penalties/repayments